UncategorizedDeadline For The Publication Of The UK CBD Novel...

Deadline For The Publication Of The UK CBD Novel Food List Slips – Once More


THE June deadline set by the UK Food Standards Agency for the publication of the Novel Food Public List of Validated CBD applications will pass today without any further updates.

This will be the third deadline the FSA has failed to achieve after initially informing the industry it expected to produce a comprehensive Validated list by the end of March, then in April, and later, by the end of June.

The ongoing uncertainty is proving to be a headache for many with major retail contracts still in limbo – as brands await approval from the UK’s food regulators. 

Yet Another Deadline Passes 

Following a call with The UK Food Standards Agency this morning BusinessCann received the following statement; 

The list will not be finalised by the end of the month as we don’t have all the information we need from some businesses to assess if their products can be added to the ‘on hold’ section of the CBD list.

“The public list will be updated when applicants have provided enough information in their applications to allow us to make a decision on validation. 

Businesses who have submitted applications by the 31 March deadline have been advised of the outstanding information required before their application can progress. It is up to the applicants to supply this information for their application to be validated and to allow the public list to be finalised.”

One industry leader told BusinessCann he is not surprised by developments: “There has been lots of false documentation provided for products that were not on the market prior to February 2020, and we’ve heard of companies whose validations have been withdrawn after submitting false data.”

At the end of May the FSA said of the 803 applications it had received with 250 of these had passed through to the Administration or Validation phases.

The first instalment of this Public List was published on April 19 and currently features four only bulk ingredient suppliers with some 43 products linked to these Validated applications.

One of these companies is Pureis Ultra Pure CBD. Acknowledging today’s developments it released the following statement: “The credibility of the UK FSA is undermined by not sticking to deadlines as it’s unfair to companies that provided all of the relevant details in time. It appears the CBD industry will continue to remain in limbo indefinitely.

What is the CBD Novel Food Process?

CBD is a thriving market set to be worth over £600m in the UK and increasingly popular in Europe, North America and the rest of the world.

In February, last year, the UK Food Standards Agency’s scientific advisors raised concerns about the safety of CBD.

It said it wanted all companies looking to sell CBD in the UK to submit applications through its Novel Food process by March 31, this year – which effectively meant applications had to be submitted by the middle of February to allow for the initial Administrative check.

The first stage of securing a Novel Food permit is the Administrative check, which is designed to ensure all the required documentation is in place, the second is Validation; ensuring it matches the requirements, including details on safety and toxicology studies and finally Authorisation.

When an application has passed through Validation, the applicant, and the products associated with that application, are published on the FSA’s Public List.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


  1. As a hemp farmer in Spain, a medical cannabis user for over 20 years, and founder of an information group Medical Cannabis Club UK over eight years ago, it is very clear to see the the International attempts to ‘hold back’ the evolution of CBD, and cannabis as a medicine. Banks refuse to process online payments, Governments still deny the medical benefits and continue to cite the dangers, Social Media organisations ban the advertising and promotion of it, even its use for animals has been restricted to a black market. All this while the patents list by the worlds biggest company GW Pharmaceuticals expands to cover nearly ALL ilnesses https://patents.justia.com/assignee/gw-pharma-limited This combined with lobbying by other Pharmaceutical companies is the reason.

Comments are closed.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you